Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 21,304	$ 49,224
Prepaid expenses and other current assets	1,118	1,019
Total current assets	22,422	50,243
Long-term assets
Property and equipment, net	33	19
Operating lease right-of-use assets	421	124
Finance lease right-of-use assets		15
Intangible assets, net	12,637	14,581
Other long-term assets	40
Total assets	35,553	64,982
Current liabilities
Accounts payable	3,254	3,489
Accrued compensation	728	1,005
Accrued clinical trial site costs	3,420	3,789
Operating lease liabilities	282	139
Other current liabilities	323	196
Total current liabilities	8,007	8,618
Long-term liabilities
Contingent liability for Essentialis purchase price	9,547	10,278
Long-term lease liabilities	175	0
Total liabilities	17,760	19,435
Commitments and contingencies (Note 8)
Stockholders’ equity
Common stock, $0.001 par value, 250,000,000 shares authorized, 79,864,310 and 79,615,692 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively.	80	80
Additional paid-in-capital	231,068	227,912
Accumulated deficit	(213,355)	(182,445)
Total stockholders’ equity	17,793	45,547
Total liabilities and stockholders’ equity	35,553	64,982
2018 PIPE Warrant Liability [Member]
Long-term liabilities
Warrant liability	$ 31	$ 539